Last reviewed 2026-04-23 · How we verify

(G) BQ-L14

National Taiwan University Hospital · FDA-approved active Small molecule

(G) BQ-L14 is a BTK inhibitor Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.

BQ-L14 is a small molecule that acts as a selective and potent inhibitor of the Bruton's tyrosine kinase (BTK).

BQ-L14 is a small molecule that acts as a selective and potent inhibitor of the Bruton's tyrosine kinase (BTK). Used for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.

At a glance

Generic name	(G) BQ-L14
Sponsor	National Taiwan University Hospital
Drug class	BTK inhibitor
Target	BTK
Modality	Small molecule
Therapeutic area	Oncology
Phase	FDA-approved

Mechanism of action

BTK is a key component of the B cell receptor signaling complex and plays a crucial role in the activation of B cells. Inhibiting BTK has been shown to be effective in treating various B cell malignancies. BQ-L14 has been designed to selectively target BTK, leading to the inhibition of B cell activation and proliferation.

Approved indications

Relapsed or refractory mantle cell lymphoma
Relapsed or refractory marginal zone lymphoma

Common side effects

Anemia
Thrombocytopenia
Neutropenia

Key clinical trials

Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

(G) BQ-L14 CI brief — competitive landscape report
(G) BQ-L14 updates RSS · CI watch RSS
National Taiwan University Hospital portfolio CI

Frequently asked questions about (G) BQ-L14

What is (G) BQ-L14?

(G) BQ-L14 is a BTK inhibitor drug developed by National Taiwan University Hospital, indicated for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.

How does (G) BQ-L14 work?

BQ-L14 is a small molecule that acts as a selective and potent inhibitor of the Bruton's tyrosine kinase (BTK).

What is (G) BQ-L14 used for?

(G) BQ-L14 is indicated for Relapsed or refractory mantle cell lymphoma, Relapsed or refractory marginal zone lymphoma.

Who makes (G) BQ-L14?

(G) BQ-L14 is developed and marketed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

What drug class is (G) BQ-L14 in?

(G) BQ-L14 belongs to the BTK inhibitor class. See all BTK inhibitor drugs at /class/btk-inhibitor.

What development phase is (G) BQ-L14 in?

(G) BQ-L14 is FDA-approved (marketed).

What are the side effects of (G) BQ-L14?

Common side effects of (G) BQ-L14 include Anemia, Thrombocytopenia, Neutropenia.

What does (G) BQ-L14 target?

(G) BQ-L14 targets BTK and is a BTK inhibitor.

Drug class: All BTK inhibitor drugs
Target: All drugs targeting BTK
Manufacturer: National Taiwan University Hospital — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Relapsed or refractory mantle cell lymphoma
Indication: Drugs for Relapsed or refractory marginal zone lymphoma

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing